Sanuwave (NASDAQ: SNWV) sees Q1 2026 revenue at $9.6–$9.7M
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Sanuwave Health, Inc. reported preliminary revenue for the quarter ended March 31, 2026 of $9.6–$9.7 million, an increase of 3–4% over the same quarter in 2025 and in line with its prior Q1 guidance.
Management noted that several larger deals slipped out of the quarter but remain active, contributing to results landing toward the lower end of the guided range. The company highlighted disruption in advanced wound care from reimbursement changes for skin substitutes and allografts, which has caused some customers to pause or scale back activity.
Sanuwave described strong practitioner interest in its Ultramist technology at a recent wound care conference and indicated it plans to “lean in” to the market rather than pull back. The company emphasized that these figures are preliminary and may change when full Q1 results are reported in May.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Preliminary Q1 2026 revenue: $9.6–$9.7 million
Year-over-year revenue growth: 3–4%
Prior guidance alignment: Within Q1 2026 guidance range
3 metrics
Preliminary Q1 2026 revenue
$9.6–$9.7 million
Quarter ended March 31, 2026
Year-over-year revenue growth
3–4%
Q1 2026 vs Q1 2025
Prior guidance alignment
Within Q1 2026 guidance range
As referenced to Q4 2025 earnings release
Key Terms
preliminary financial results, forward-looking statements, Private Securities Litigation Reform Act of 1995, reimbursement for skin substitutes and allografts, +1 more
5 terms
preliminary financial results financial
"issued a press release announcing certain preliminary financial results for the quarter"
Preliminary financial results are an early, unaudited summary of a company’s recent revenue, profits and key financial figures released before the final, checked reports. Think of it as a draft snapshot that gives investors a quick look at performance; it matters because it can change market expectations, influence stock price and guide short-term decisions, but the numbers may be adjusted when independently verified.
forward-looking statements regulatory
"This press release may contain “forward-looking statements” within the meaning"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Private Securities Litigation Reform Act of 1995 regulatory
"within the meaning of the Private Securities Litigation Reform Act of 1995"
reimbursement for skin substitutes and allografts financial
"changes in reimbursement for skin substitutes and allografts and this has caused many"
advanced wound care medical
"activities in advanced wound care. But, as we discussed on our Q4 call"
Specialized products and treatments used to heal hard-to-close or long-lasting wounds, such as advanced dressings, engineered tissue patches and devices that control infection and support tissue repair. For investors, advanced wound care matters because it is a higher-value, fast-evolving segment where clinical results, regulatory clearance and insurance reimbursement drive sales, margins and recurring revenue—similar to a specialized toolkit that can replace basic care and reduce overall healthcare costs.
Earnings Snapshot
Revenue: $9.6–$9.7 million · Guidance included
Q1 2026
Revenue
$9.6–$9.7 million
+3–4% YoY
Guidance
Preliminary Q1 2026 revenue is within the prior guidance range.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
| Date of Report (Date of earliest event reported) | |||||
| (Exact name of registrant as specified in its charter) | ||
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
| (Address of principal executive offices) | (Zip Code) | ||||||||||
| Registrant’s telephone number, including area code | ||||||||
| N/A | ||
| (Former name or former address, if changed since last report) | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
| Common stock, par value $0.001 per share | SNWV | The Nasdaq Stock Market LLC | ||||||
Indicate by check mark whether the registration is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
1
Item 2.02 Results of Operations and Financial Condition.
On April 16, 2026, Sanuwave Health, Inc., a Nevada corporation (the “Company”), issued a press release announcing certain preliminary financial results for the quarter ended March 31, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
Exhibit No. | Description | |||||||
99.1 | Press Release dated April 16, 2026 | |||||||
| 104 | Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document. | |||||||
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| SANUWAVE HEALTH, INC. | ||||||||
| Dated: April 16, 2026 | By: | /s/ Peter Sorensen | ||||||
| Name: | Peter Sorensen | |||||||
| Title: | Chief Financial Officer | |||||||
3
Exhibit 99.1
Sanuwave Health Reports Preliminary Q1 2026 Revenue of $9.6–$9.7 Million, Up 3-4% Year-over-Year
Sanuwave is pleased to announce preliminary revenues of $9.6 million to $9.7 million for the first quarter ended March 31, 2026, in line with prior guidance for Q1.
EDEN PRAIRIE, MN, April 16, 2026 (GLOBE NEWSWIRE) Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of FDA-approved directed energy systems used in advanced wound care, today announced that revenues for the first quarter of 2026 are expected to be in the range of $9.6 to $9.7 million, an increase of 3-4% over Q1 2025. This number is within the range of guidance given in the Company’s Q4 2025 earnings release issued on March 26, 2026.
“At the end of Q1 the Company saw several good-sized deals (all of which remain live) slide out of the quarter and this brought us in toward the lower end of our guidance range,” said CEO Morgan Frank. “Q1 has been a sort of reckoning in the wound care space as practitioners and customers came to terms with some significant changes in reimbursement for skin substitutes and allografts and this has caused many market participants and practitioners to pause or pull back from their activities in advanced wound care. But, as we discussed on our Q4 call, the patients and the wounds have not gone away and the need for care remains. At the SAWC conference in Charlotte last week, we spoke to a great many practitioners who were asking ‘So what now?’ and looking for options going forward. Our booth was as busy as any of us can ever recall seeing it, our hands-on workshops were full, and interest was high. For these reasons, we’re not pulling back but rather leaning in as we believe that Ultramist can be an important part of the forward roadmap for patient care. I’m not sure we can quite say ‘the tide has fully turned’ at this point, but, at the very least, it does seem like perhaps the turn is starting and our optimism is increasing. We look forward to speaking with you further on this and providing some more color when we report our Q1 number in May.”
The preliminary revenue results described herein are based on management’s initial analysis of the first quarter ended March 31, 2026, and may be subject to adjustments based on the Company’s completion of its quarter-end financial close process.
About Sanuwave
Sanuwave Health is focused on the research, development, and commercialization of its patented, non-invasive directed energy systems used in the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.
Sanuwave's end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing processes. Sanuwave applies and researches its patented and FDA approved/cleared energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations, plans for future business development activities and expectations regarding the impact of changes in tariff rates. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with regulatory oversight, the Company’s ability to manage its capital resources, competition and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
Contact: investors@sanuwave.com
FAQ
What preliminary Q1 2026 revenue did Sanuwave Health (SNWV) report?
Sanuwave Health reported preliminary Q1 2026 revenue of $9.6–$9.7 million. This represents 3–4% year-over-year growth versus Q1 2025 and falls within the company’s previously issued guidance range for the quarter.
How does Sanuwave’s Q1 2026 revenue compare to prior guidance?
Sanuwave’s preliminary Q1 2026 revenue of $9.6–$9.7 million is stated as being within its prior guidance range. Management said deal timing pushed results toward the lower end but kept them consistent with earlier expectations.
What market conditions affected Sanuwave Health’s Q1 2026 performance?
Management cited a “reckoning” in wound care due to reimbursement changes for skin substitutes and allografts. These shifts caused many practitioners and customers to pause or pull back on advanced wound care activity, affecting deal timing in the quarter.
How is Sanuwave responding to changes in the wound care reimbursement environment?
Sanuwave plans to “lean in” rather than pull back, positioning its Ultramist technology as part of future treatment options. The company reported strong practitioner interest at a recent SAWC conference and sees ongoing need for advanced wound care solutions.
Are Sanuwave Health’s Q1 2026 financial figures final?
No. Sanuwave described the Q1 2026 revenue figures as preliminary, based on management’s initial analysis. The company indicated that results may be adjusted after completing its quarter-end close and will be finalized when full Q1 results are reported.
What risks did Sanuwave highlight alongside its preliminary Q1 results?
Sanuwave included forward-looking statement language citing risks such as regulatory oversight, capital resource management, competition, and broader uncertainties. It referenced factors discussed in its periodic SEC filings as key elements that could affect future performance.